Invest in 10,000+ US Stocks and ETFs
* Offering through VF Securities, Inc. (member FINRA/SIPC)
Intra-Cellular Therapies, Inc., a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States. The company offers CAPLYTA for the treatment of schizophrenia and bipolar depression in adults. It is also involved in developing Lumateperone, which is in Phase 3 clinical trial for the treatment of various depressive disorders, as well as additional neuropsychiatric indications. In addition, the company is developing Lenrispodun (ITI-214) for the treatment of Parkinson's disease, CNS, and other disorders; ITI-1284 for the treatment of neuropsychiatric disorders and behavioral disturbances in dementia; and ITI-333 for substance use disorders, pain, and psychiatric comorbidities, including depression, anxiety, and sleep disorders. Intra-Cellular Therapies, Inc. was founded in 2002 and is headquartered in New York, New York. more
Time Frame | ITCI | Sector | S&P500 |
---|---|---|---|
1-Week Return | 0.18% | -3.72% | -0.05% |
1-Month Return | 3.2% | -1.85% | 2.75% |
3-Month Return | 13.09% | -11.4% | 7.4% |
6-Month Return | 23.58% | -4.41% | 10.47% |
1-Year Return | 30.42% | 4.13% | 27.57% |
3-Year Return | 130.21% | 0.3% | 29.56% |
5-Year Return | 559.26% | 36.62% | 89.3% |
10-Year Return | 440.38% | 106.81% | 206.09% |
Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | 5YR TREND | |
---|---|---|---|---|---|---|
Total Revenue | 60.61K | 22.53M | 81.71M | 249.13M | 464.37M | [{"date":"2019-12-31","value":0.01,"profit":true},{"date":"2020-12-31","value":4.85,"profit":true},{"date":"2021-12-31","value":17.6,"profit":true},{"date":"2022-12-31","value":53.65,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Cost of Revenue | 89.12M | 1.90M | 8.03M | 20.44M | 33.74M | [{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":2.13,"profit":true},{"date":"2021-12-31","value":9.01,"profit":true},{"date":"2022-12-31","value":22.94,"profit":true},{"date":"2023-12-31","value":37.86,"profit":true}] |
Gross Profit | 60.61K | 20.64M | 73.67M | 228.69M | 430.63M | [{"date":"2019-12-31","value":0.01,"profit":true},{"date":"2020-12-31","value":4.79,"profit":true},{"date":"2021-12-31","value":17.11,"profit":true},{"date":"2022-12-31","value":53.11,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Gross Margin | 100.00% | 91.59% | 90.17% | 91.79% | 92.73% | [{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":91.59,"profit":true},{"date":"2021-12-31","value":90.17,"profit":true},{"date":"2022-12-31","value":91.79,"profit":true},{"date":"2023-12-31","value":92.73,"profit":true}] |
Operating Expenses | 154.07M | 251.86M | 359.36M | 492.31M | 590.01M | [{"date":"2019-12-31","value":26.11,"profit":true},{"date":"2020-12-31","value":42.69,"profit":true},{"date":"2021-12-31","value":60.91,"profit":true},{"date":"2022-12-31","value":83.44,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Operating Income | (154.01M) | (231.23M) | (285.69M) | (263.63M) | (159.38M) | [{"date":"2019-12-31","value":-15401185000,"profit":false},{"date":"2020-12-31","value":-23122763100,"profit":false},{"date":"2021-12-31","value":-28568812500,"profit":false},{"date":"2022-12-31","value":-26362600000,"profit":false},{"date":"2023-12-31","value":-15938100000,"profit":false}] |
Total Non-Operating Income/Expense | 12.58M | 8.47M | 3.14M | 14.75M | 40.69M | [{"date":"2019-12-31","value":30.93,"profit":true},{"date":"2020-12-31","value":20.82,"profit":true},{"date":"2021-12-31","value":7.71,"profit":true},{"date":"2022-12-31","value":36.26,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Pre-Tax Income | (147.72M) | (226.99M) | (284.12M) | (256.25M) | (139.04M) | [{"date":"2019-12-31","value":-14772057800,"profit":false},{"date":"2020-12-31","value":-22699215000,"profit":false},{"date":"2021-12-31","value":-28412003500,"profit":false},{"date":"2022-12-31","value":-25625000000,"profit":false},{"date":"2023-12-31","value":-13903800000,"profit":false}] |
Income Taxes | 1.60K | 13.51K | 5.63K | 6.00K | 636.00K | [{"date":"2019-12-31","value":0.25,"profit":true},{"date":"2020-12-31","value":2.12,"profit":true},{"date":"2021-12-31","value":0.89,"profit":true},{"date":"2022-12-31","value":0.94,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Income After Taxes | (147.72M) | (227.01M) | (284.13M) | (256.26M) | (139.67M) | [{"date":"2019-12-31","value":-14772217800,"profit":false},{"date":"2020-12-31","value":-22700566300,"profit":false},{"date":"2021-12-31","value":-28412566600,"profit":false},{"date":"2022-12-31","value":-25625600000,"profit":false},{"date":"2023-12-31","value":-13967400000,"profit":false}] |
Income From Continuous Operations | (147.72M) | (227.01M) | (284.13M) | (256.26M) | (139.67M) | [{"date":"2019-12-31","value":-14772217800,"profit":false},{"date":"2020-12-31","value":-22700566300,"profit":false},{"date":"2021-12-31","value":-28412566600,"profit":false},{"date":"2022-12-31","value":-25625600000,"profit":false},{"date":"2023-12-31","value":-13967400000,"profit":false}] |
Income From Discontinued Operations | - | - | - | - | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Net Income | (147.72M) | (227.01M) | (284.13M) | (256.26M) | (139.67M) | [{"date":"2019-12-31","value":-14772217800,"profit":false},{"date":"2020-12-31","value":-22700566300,"profit":false},{"date":"2021-12-31","value":-28412566600,"profit":false},{"date":"2022-12-31","value":-25625600000,"profit":false},{"date":"2023-12-31","value":-13967400000,"profit":false}] |
EPS (Diluted) | (2.68) | (3.24) | (3.50) | (2.72) | (1.46) | [{"date":"2019-12-31","value":-268,"profit":false},{"date":"2020-12-31","value":-324,"profit":false},{"date":"2021-12-31","value":-350,"profit":false},{"date":"2022-12-31","value":-272,"profit":false},{"date":"2023-12-31","value":-146,"profit":false}] |
These ratios help you determine the liquidity of the company. Higher is better.
ITCI | |
---|---|
Cash Ratio | 6.06 |
Current Ratio | 7.66 |
Quick Ratio | 7.51 |
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
ITCI | |
---|---|
ROA (LTM) | -7.45% |
ROE (LTM) | -9.90% |
These ratios help you understand the company's liabilities, gauging the riskiness of the investment.
ITCI | |
---|---|
Debt Ratio Lower is generally better. Negative is bad. | 0.14 |
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. | 0.86 |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
ITCI | |
---|---|
Trailing PE | NM |
Forward PE | 208.33 |
P/S (TTM) | 14.34 |
P/B | 7.69 |
Price/FCF | NM |
EV/R | 12.75 |
EV/Ebitda | NM |
PEG | NM |
Intracellular Th (ITCI) share price today is $85.11
Yes, Indians can buy shares of Intracellular Th (ITCI) on Vested. To buy Intracellular Th from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in ITCI stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.
Yes, you can purchase fractional shares of Intracellular Th (ITCI) via the Vested app. You can start investing in Intracellular Th (ITCI) with a minimum investment of $1.
You can invest in shares of Intracellular Th (ITCI) via Vested in three simple steps:
The 52-week high price of Intracellular Th (ITCI) is $93.45. The 52-week low price of Intracellular Th (ITCI) is $62.78.
The price-to-earnings (P/E) ratio of Intracellular Th (ITCI) is
The price-to-book (P/B) ratio of Intracellular Th (ITCI) is 7.69
The dividend yield of Intracellular Th (ITCI) is 0.00%
The market capitalization of Intracellular Th (ITCI) is $8.80B
The stock symbol (or ticker) of Intracellular Th is ITCI